

---

## Index

- A3M4 mab 248–9  
 A9 mab 250–1  
 AA3 polyclonal antibody 369  
 acetone fixation 444, 445  
 acetylcholine receptor Humab 93  
 acrylamide stock 462  
 activin-A 382  
 adenosine deaminase-binding protein 189  
 adenoviruses 248, 249  
 adhesion molecules 405–6  
   mab against  
     animal models of autoimmunity 307, 308  
     rheumatoid arthritis 413, 415  
     transplant recipients 344–5  
     skin cells 372–3  
     transplanted organs 285–7  
 adjuvants 12, 429  
 adrenocorticotrophic hormone (ACTH) 384, 385  
 adriamycin 236  
 AE1/AE2/AE3 mab 364–5  
 AF1/AF2 mab 370  
 affinity 34–7  
   mab used in immunoassays 383–4  
   multivalency 44–8  
   on/off rates 37–8  
   parameters affecting 44–50  
   sensitivity 44  
 affinity chromatography  
   hormone receptors 389  
   IgG subclasses 453  
   mab purification 28–9, 451–3  
 affinity maturation 2  
   phage-derived antibodies 150, 151–2  
 affinity purification, hormones 393  
 age, hosts for immunization 14  
 AIDS 253–5, 268  
 $\beta$ -alanine 71–3  
 aldehyde fixatives 53  
 alkaline phosphatase 197–8  
   isoenzyme assays 187  
   mab screening assay 21, 446–8  
 $\alpha_1$ -antitrypsin 186–7  
 ambient analyte immunoassay 199  
 Amido Black 464, 465  
 amines, antibodies to 52  
 amino acids  
   F<sub>moc</sub>-protected 71–3  
   radiolabelled 32  
   synthetic peptides 62  
 aminopterin (A) 19  
 ammonium persulphate 463  
 ammonium sulphate 27  
 amygdalin 237  
 animal models  
   autoimmune diseases, *see* autoimmune diseases, animal models  
   rheumatological disorders 408–10  
 anti-immune complex immunoassay 189, 190  
 anti-lymphocyte polyclonal gammaglobulins (ALG) 340  
 anti-mouse antibodies 228, 234  
   human (HAMA) 90, 155, 233–4, 418  
 antibiotics 260, 263–4, 430  
 antibodies 1  
   generation of repertoire 4–5  
   production 1–2  
   structure 2–4  
   *see also* antigen–antibody interactions; monoclonal antibodies; polyclonal antibodies  
 antibody-dependent cell-mediated cytotoxicity (ADCC) 134, 229–30  
 antibody fragments  
   bispecific 126, 157–8, 159  
   bivalent 159, 160  
   immunoassays 191–2  
   phage display 147–8  
   recombinant 154–9, 170–5  
     engineering effector functions 157–8  
     nature 155  
     production 154–5, 172–5  
   tumour imaging 155, 223, 226–7  
   tumour therapy 232  
   *see also* Fab fragments; F(ab')<sub>2</sub> fragments; Fv fragments; single-chain Fv fragments  
 antigen(s) 9–11  
   amount  
     concentration of mab used and 49–50  
     per immunization 429, 430  
   analysis of target 31–2  
   chemical structure 11

- antigen(s) (*cont.*)  
 conformation 11  
 conjugation to carriers 10, 52  
 fixation 52–3, 444, 445  
 heterogeneity 10–11  
 immunodominant 11  
 liquid phase 56  
 multiple mab binding to different epitopes 47–8, 56  
 production 12  
 size 10  
 solid phase 56  
 binding to single antibody 44–7  
 toxic/poorly immunoreactive 202  
*see also* immunization
- antigen–antibody interactions 34–57  
 affinity, *see* affinity  
 epitopes and 50–3  
 kinetics 37–40  
 optimizing 56–7  
 sensitivity 41–4  
 specificity 53–6
- antigen-presenting cells (APCs) 10, 403  
 mab therapies against 302–3  
 T cell interactions 404
- antigenic determinants, *see* epitopes  
 antigenic modulation 122
- antiglobulin response 418–19  
*see also* human anti-mouse antibodies
- antithymocyte globulin (ATG)  
 graft-versus-host disease and 319, 325  
 transplant recipients 342, 343, 348–9, 350, 352
- arginine vasopressin (AVP) 386, 388
- ART18 mab 301
- ascites method 14, 25–6, 441  
 Humab production 105
- aspergillosis 255
- association constant ( $K_a$ ) 34–6
- association rate constant 38
- astatine-211 ( $^{211}\text{At}$ ) 232
- astroviruses 249
- autoantibodies, interference in immunoassays 192
- autoimmune diseases 406  
 analysis of antigenic epitopes 387–8  
 animal models 292–309  
 adhesion molecule-directed mab 307, 308  
 antigen-presenting cell-directed mab 302–3, 304–5  
 cytokine-directed mab 305–8  
 miscellaneous mab 308, 309  
 T cell directed mab 294–303, 406, 407  
 cell surface antigens 388  
 hormone receptor antibodies 389  
 Humab derived 92–3  
*see also* rheumatological disorders; *specific diseases*
- avidin, *see* biotin–avidin systems
- azathioprine (AZA) 284, 348–9, 350
- B7.21 mab 278  
 B.72.3 mab 227
- B220 mab 308, 309
- B-B10 mab 327
- B cell stimulating factor (BSF-2) 394
- B lymphocytes  
 activation 1–2, 10  
 generation of antibody repertoire 4–5  
 human, *see* human B lymphocytes  
 memory 2, 149  
 phage display libraries and 149–51  
 sources 14  
 transplanted organs 274
- bacteria  
 antigen/toxin-directed Humab 97  
 expression systems 152–3, 154–5, 173–4  
 tissue culture contamination 430–1
- bacterial infections  
 diagnosis 248, 249, 250–1  
 prophylaxis and therapy 261–6
- basement membrane zone (BMZ), skin 368–70
- beta<sub>2</sub>-microglobulin 201, 285
- Bio-Enzabead Screen Kit 249
- bioassays, hormone 380–1
- biosensors 201
- biotin–avidin systems 42–4  
 mab screening assays 22  
 tumour imaging 228–9  
 tumour therapy 237
- bis-diazotized tolidine (Bdt) 64–5, 80–1
- bismuth-212 ( $^{212}\text{Bi}$ ) 232
- bispecific antibodies 121–36, 352  
 applications 122, 132–6, 201  
 genetically engineered 126–31, 134–5, 157–8, 159  
 mixed-isotype 134–5  
 production 123–31  
 single-chain 131  
 tumour imaging 122, 228  
 tumour therapy 122, 132, 133, 230, 236  
 universal 135–6
- bivalent antibody fragments 159, 160
- BL4 mab 347, 411
- blood group reagents 91, 92
- bone marrow  
 T cell depletion of donated 319–25  
 toxicity, selective radiotherapy 233–4
- bone marrow transplantation (BMT) 317–29, 344, 345  
 indications 317  
 rejection 318–19  
 results 317  
*see also* graft-versus-host disease
- bovine serum albumin 63, 64
- brain tumours 235
- breast cancer 215, 226, 391
- bromophenol blue 463
- bulk production  
 Humab 105–6  
 mab 25–6, 440–1
- bullous pemphigoid antigen 368, 369
- Ca1 antibody 213
- calgranulins 365
- CAM 5.2 mab 365

- Campath-6 350, 413  
 Campath-I 321–2, 346  
   antigen 169, 413  
   humanized, *see* Campath-IH  
 Campath-IG 418–19  
 Campath-IH 169, 170, 351  
   adverse effects 417, 418–19  
   rheumatoid arthritis 413  
   systemic vasculitis 416  
 cancer chemotherapeutic agents  
   amplification of tumour localization 237–8  
   antibody conjugates 235–6  
   bispecific mab to 133, 236  
 cancer therapy, *see* tumour therapy  
 candidosis 255  
 carbodiimides (CDI) 65, 81  
 carbohydrates 11  
 carboxymethyl (CM) cellulose 28  
 carcinoembryonic antigen (CEA)  
   bispecific mab 130, 133  
   tumour localization and 223, 228  
   tumour therapy and 234, 235  
 carrier proteins 10, 63–4  
 catalytic antibodies 155  
 cation exchange chromatography 28  
 CBL1 mab 345–6  
 CD1 368  
 CD2 373, 404  
 CD2 mab  
   animal model of diabetes 308, 309  
   graft-versus-host disease prophylaxis 320,  
     322, 323–4  
   graft-versus-host disease therapy 327  
 CD3 404  
 CD3 mab 275  
   allograft immunohistology 276  
   animal models of autoimmunity 300  
   bispecific 133, 134, 135, 158  
   graft-versus-host disease prophylaxis 320,  
     322, 323, 325  
   graft-versus-host disease therapy 326–7  
   transplant recipients 341–4  
 CD4 49, 346, 404  
 CD4 mab 275  
   adverse effects 410, 418  
   animal models of autoimmunity 294–5,  
     296–7, 406  
   animal models of rheumatological disorders  
     408, 409–10  
   autoimmune diseases 416–17  
   bispecific 133, 158  
   diagnosis of dermal infiltrates 371  
   graft-versus-host disease prophylaxis 320, 321  
   infectious diseases 268  
   rheumatoid arthritis 410–12  
   systemic lupus erythematosus 415  
   systemic vasculitis 416  
   tolerance induction 406–7  
   transplant recipients 346–7, 353  
 CD4 T cells  
   adverse effects of depletion 417–18  
   graft-versus-host disease 328–9  
   rheumatological disorders 408, 409  
   transplanted organs 274–5, 276  
 CD5 mab  
   experimental allergic encephalomyelitis 308,  
     309  
   graft-versus-host disease prophylaxis 320,  
     323, 324  
   graft-versus-host disease therapy 328  
 CD5 plus 413–14, 415  
 CD6 mab 320, 325, 341  
 CD7 mab  
   cutaneous T cell lymphoma 371  
   graft-versus-host disease prophylaxis 320, 323  
   rheumatoid arthritis 412, 413  
   transplant recipients 345, 351  
 CD8 mab 275  
   animal model of arthritis 297, 409, 410  
   animal models of autoimmunity 295–300  
   bispecific 133  
   diagnosis of dermal infiltrates 371  
   graft-versus-host disease prophylaxis 320,  
     321, 323, 325  
   tolerance induction 407  
 CD8 T cells  
   graft-versus-host disease 328–9  
   transplanted organs 274–5, 276  
 CD11a mab 320, 326, 344–5  
 CD11b mab 275  
 CD15 212  
 CD16 mab 275  
 CD18 mab 344  
 CD22 mab 236  
 CD25, *see* interleukin 2 receptors  
 CD28 404  
 CD31 (PECAM) 280, 282, 285–7  
 CD43 49  
 CD45 mab 275  
 CD54, *see* intercellular adhesion molecule  
 CD57 mab 275  
 cell culture  
   contamination 430–1  
   general techniques 429–30  
 cell proliferation markers 215–16  
 cell sorting  
   cloning 23, 440  
   endocrinology 386–7  
 cellular infiltrates  
   skin 370–2  
   transplanted organs 274–6  
 chain shuffling 151–2  
 Chal 1 mab 346  
 characterization  
   hormone receptors 389  
   mab 26–30, 449–58  
 chemical cross-linking  
   affinity and 48  
   fixation by 53  
 chemiluminescent techniques 42, 198, 199  
 chimeric antibodies 157, 167, 171  
   antiglobulin response 418  
   bispecific 128–30  
   expression 174  
   production 168  
   transplant recipients 351–2  
 chlamydial infections 99  
   diagnosis 97, 248, 252–3

- chlamydial infections (*cont.*)  
   prophylaxis and therapy 266–8  
 chorionic gonadotrophin (hCG) 186, 196, 383–4  
 chromatography  
   affinity, *see* affinity chromatography  
   mab purification 27–9, 451–3, 455–7  
 chromosome loss 17  
   human 102, 167  
   hybrid hybridoma cells 125  
 cloning techniques 22–3, 24, 436–40  
   Humab production 104–5  
   limiting dilution, *see* limiting dilution  
   single cell manipulation 23, 439–40  
   soft agar 438–9  
*Clostridium difficile* 249  
 collagen type IV 368, 369  
 colon carcinoma  
   localization 223  
   therapy 133, 235, 236  
 colorimetric detection systems 198  
 complement (C'), graft-versus-host disease  
   prophylaxis 320, 321–3  
 complement-mediated cytotoxicity (CMC)  
   229–30  
 complementarity-determining region (CDR)  
   grafting 167, 168–70, 171  
 complementarity determining regions (CDRs)  
   3–4  
   minimal recognition units derived from 175  
 concanavalin A 145  
 concentration of mab  
   antibody specificity and 54–6  
   determination 29  
   kinetics of antibody–antigen reactions and  
     39–40  
 congenital infections 250–2  
 conjugation  
   antibodies to effector compounds 121–2  
   antigens to carrier macromolecules 10, 52  
   chemical, between antibody molecules 125–6  
   synthetic peptides to carriers 63–5, 78–82  
 constant (C) domains 3  
 corticotrophin-releasing factor (CRF) 388, 394  
 cortisol 185  
 CR3 receptor mab 304, 305  
 creatine kinase  
   CK-MB isoenzyme 187  
   CK-MM isoenzyme 130  
 cryopreservation 431–3  
   hybridoma cells 24–5, 431–2  
   mab 30  
   myeloma cells 16, 433  
 cryoprotectants 24–5, 432  
 cryostat sections 443–4  
*Cryptococcus neoformans* 255, 268  
*Cryptosporidium parvum* (cryptosporidiosis)  
   255, 268  
 CT-2 antibodies 320, 322, 323  
 cutaneous T cell lymphoma (CTCL) 227, 371  
 cyanogen bromide (CNBr)-activated sepharose  
   4B, mab coupling to 457–8  
 cyclosporine (CsA)  
   animal models of autoimmunity 303  
   graft-versus-host disease prophylaxis 319, 325  
   transplant recipients 275, 284, 349, 350  
 cysteines 62, 159  
 cytokines 404–5  
   immunoassays 385  
   mab against  
     autoimmune diseases 305–8  
     neutralizing 394  
     rheumatoid arthritis 413, 414  
   OKT3-induced release 342–3  
   transplanted organs 287  
 cytomegalovirus (CMV) infections  
   diagnostic assays 252, 254  
   therapy 96, 266–7  
   transplant recipients 276, 349, 353  
 cytopins 444, 445  
   isotyping on 449–50  
   storage 445  
 DAB<sub>486</sub>IL-2 fusion toxin 412  
 DEAFF test 254  
 dehydroxyepiandrosterone (DHEA) sulphate  
   185  
 delta agent 250  
 denaturation, protein 51  
 detection systems  
   immunoassays 197–201  
   inherent sensitivity 41–2  
 diabetes mellitus  
   animal models  
     adhesion molecule-directed mab 307, 308  
     anti-CD2 mab 308, 309  
     anti-CD3 mab 300  
     anti-CD4 mab 294–5, 296, 406  
     anti-CD8 mab 295, 298–9  
     anti-IL-2R mab 301  
     anti-interferon- $\gamma$  mab 305, 306  
     anti-T cell receptor mab 298, 299, 300  
     antigen-presenting cell-directed mab 302,  
       304, 305  
     pan T cell mab 293, 294  
   Humab generation 92, 93  
   insulin antibodies 393  
   pancreas/kidney transplantation 350  
   proinsulin cleavage molecules 385  
 3,3'-diamino-benzidine tetrahydrochloride  
   (DAB) 21, 446, 466  
 diethylaminoethyl (DEAE) cellulose beads 28  
 diethylenetriaminepentaacetic acid (DTPA)  
   225, 233  
 differentiation, tumour 216–18  
 digoxin 190  
 dilution  
   antibody 54–6, 57  
   doubling 23  
   limiting 23, 104–5, 436–8  
 dimethylsulphoxide (DMSO) 24–5, 432  
 dinitrophenol 100, 189  
 diphtheria toxin 97, 412  
 dissociation constant ( $K_d$ ) 36–7  
 dissociation rate constant 38  
 disulphide bonds 159, 174  
 dithiothreitol 384  
 Dot blot assays  
   isotype determination 26

- screening 21  
 doubling dilution 23  
 doxorubicin 236  
  
 E5 mab 264  
 E-selectin (ELAM-1) 285, 287, 372–3, 415  
 EBV, *see* Epstein–Barr virus  
 ED7/ED8 mab 304, 305  
 effector cell targeting, bispecific mab 132–3  
 effector compounds  
   conjugation of antibodies to 121–2  
   targeting by bispecific mab 122, 133–4  
 effector functions, engineered onto antibody fragments 157–8  
 electrochemical detection systems 198  
 electrofusion 17, 101  
 ELISA, *see* enzyme-linked immunosorbant assay  
 encephalitis 251–2  
 encephalomyelitis, experimental allergic, *see* experimental allergic encephalomyelitis  
 endocardial cushions of cells 276, 277  
 endocrine cells  
   cell surface determinants 388  
   flow cytometry 386–7  
 endocrinology 380–95  
   generation of suitable mab 382–3  
   use of mab 383–95  
   *see also* hormones  
 endothelial cells 405–6  
   ICAM-1 expression 373  
   MHC antigen expression 280–2  
 endothelial leukocyte adhesion molecule-1 (ELAM-1; E-selectin) 285, 287, 372–3, 415  
 endotoxin (lipopolysaccharide; LPS) 261–2, 265  
   core 261–2, 264  
   lipid A 96, 261–2, 264  
   mab against 96, 261–4  
   ‘O-specific’ side chain 262, 263  
 enrichment, human B lymphocytes 98  
 enteroviruses 251  
 enzyme–antibody fusion proteins 158  
 enzyme-based detection systems  
   immunoassays 180–1, 197–8, 199  
   immunohistochemistry 22  
   sensitivity 41  
 enzyme-linked immunosorbant assay (ELISA)  
   bispecific mab 132  
   coating buffer 443  
   isotype determination 26  
   screening assays 21, 22, 66–7, 441–3  
 enzyme–prodrug systems, tumour therapy 237–8  
 epidermal growth factor (EGF) receptors 215, 391  
 epidermolysis bullosa (EB) 369–70  
   acquisita (EBA) 370  
   dystrophic (DEB) 369–70  
   junctional (JEB) 369  
   simplex 369  
 epitope scanning 70  
 epitopes 1, 50–3  
   analysis in autoimmune disease 387–8  
   detection and analysis 69–77  
   mapping, hormonal receptors and ligands 389–90  
   multiple antibodies binding to different 47–8, 56  
   prediction and selection 61–3  
 Epstein–Barr virus (EBV)  
   combined transformation/fusion technique 89, 103–4  
   detection 250  
   transformation of B cells 87–8, 103, 167–8  
   transformed lymphoblastoid cell lines (LCL) 86, 88  
*c-erbB-2* 215  
 erythropoietin (EPO) 394  
*Escherichia coli*  
   antibody display 152–3  
   diagnostic assay 249  
   expression systems 131, 173–4  
   infections, therapy 96, 97, 261–4, 265  
 1-ethyl-3-(diethylaminopropyl)-carbodiimide (EDC) 81  
 evanescent wave immunoassay 200  
 experimental allergic encephalomyelitis (EAE)  
   adhesion molecule-directed mab 307, 308  
   anti-CD4 mab 294, 296  
   anti-CD5 mab 308, 309  
   anti-CD8 mab 295, 299  
   anti-MHC class II mab 302–3, 304  
   anti-T cell receptor mab 299, 300–2  
   macrophage-directed mab 304, 305  
   T cell activation marker mab 301, 303  
 experimental allergic uveitis (EAU)  
   adhesion molecule-directed mab 307, 308  
   anti-MHC class II mab 303, 304  
   cytokine-directed mab 305, 306  
   macrophage-directed mab 304, 305  
 experimental autoimmune myasthenia gravis (EAMG) 294, 297, 406  
 experimental autoimmune neuritis (EAN) 293, 294, 295, 297, 299  
 experimental autoimmune thyroiditis (EAT)  
   anti-CD4 mab 294, 297  
   anti-CD8 mab 295, 299  
   anti-MHC class II mab 303, 304  
   anti-T cell receptor mab 299, 302  
   cytokine-directed mab 305, 306  
 expression systems  
   antibody fragments 152–3, 154–5, 173–4  
   bispecific mab 131  
 expression vectors 144–6, 173  
 extinction coefficient 29  
  
 F<sub>1</sub> hybrids 13  
 F10-89-4 mab 275, 280  
 F23.1 mab 299, 300  
 Fab fragments 156  
   bispecific mab 126  
   bivalent 159, 160  
   engineering of effector functions 157–8  
   expression 174  
   from phage display libraries 155  
   phage display 148  
   uses 155, 227, 236

- F(ab')<sub>2</sub> fragments  
 animal model of SLE 408  
 preparation 154–5, 453–5  
 transplant recipients 343–4, 347  
 tumour imaging 227  
 fast blue BB salt 21, 448  
 fast red TR 21, 447–8  
 feeder cells 18, 435  
 Humab production 104  
 fetal calf serum (FCS) 18, 24–5, 106, 432  
 fibre optic sensors 201  
 fibrinogen receptor 175  
 fibroblasts 14  
 53–6.7 mab 298, 299  
 first dose response, T cell mab 410, 419  
 5C6 mab 304, 305  
 fixation  
 antigens 52–3, 444, 445  
 tumour pathology and 211–12  
 flow cytometry  
 endocrinology 386–7  
 screening of mab 22  
 fluorenylmethoxycarbonyl (Fmoc) amino acids  
 71–3  
 fluorescence activated cell sorter (FACS) 440  
 fluorescence-amplified enzyme-linked  
 immunoassay (FAELIA) 198, 199  
 fluorescence energy transfer technique 201  
 fluorimetry, time resolution 199  
 fluorochromes 22, 386  
 Fmoc amino acids 71–3  
 food poisoning 249  
 freezing, *see* cryopreservation  
 Freund's adjuvant 429  
 complete 12  
 incomplete 12, 25  
 fungal infections 255  
 fungi, tissue culture contamination 431  
 fusion, cell 15–18, 433–6  
 bispecific mab production 123–5  
 choice of method 17  
 combined Epstein–Barr virus/fusion  
 technique 89, 103–4  
 human–heterohybridoma 87, 88, 103  
 human–human 85–6, 101–2, 167  
 human–mouse 87, 102, 167  
 materials 433  
 medium 18  
 method 433–6  
 partners 15–16, 101–2  
 fusion proteins 157–8  
 transplant recipients 352  
 fusogens (fusion agents) 17, 85, 101  
 Fv fragments 170, 171  
 bispecific mab production 126  
 expression systems 173–4  
 single chain, *see* single chain Fv fragments
- gastric carcinoma 216  
 gastroenteritis 248–9  
 GB3 mab 369  
 GD2 ganglioside 94  
 genetic engineering 166–77, 202, 351–2, 419  
 bispecific mab 126–31, 134–5, 157–8, 159  
 effector functions onto antibody fragments  
 157–8  
 humanization 127, 166–70  
 genotype 209–10  
*Giardia lamblia* (giardiasis) 255, 268  
 glucocorticoid receptors 391  
 glucocorticoids 392  
 glutamine 62  
 glutaraldehyde 53, 64, 78–9  
 glycolalicin 187–8  
 glycoproteins 11  
 glycosylation 185–6  
 GM 4672 fusion partner 86, 102  
 gonadotrophins 384  
 gonorrhoea 253  
 graft rejection  
 bone marrow transplantation 318–19  
 cellular infiltrates and 274–5, 276  
 mab therapy/prophylaxis 340–53  
 MHC antigen expression and 279, 282–5  
 graft-versus-host disease (GVHD) 317–29  
 acute 317–18  
 chronic 318  
 diagnosis 328–9  
 future prospects 329  
 prevention 319–26, 329, 344, 345  
*in vitro* T cell depletion 319–24  
*in vivo* mab therapies 325–6  
 pharmacological methods 319, 324–5  
 treatment 319, 326–8  
 graft-versus-leukaemia effect 329  
 Gram-negative sepsis 261–6  
 Graves' disease 92–3, 389, 392  
 growth hormone (GH) 392, 393  
 assays 384  
 functional analysis 390  
 mab enhancing activity 395  
 phage display 146  
 GY15.195 mab 302
- H3a mab 370  
 HA-1A mab 263, 264  
 haemagglutination assay 26  
 haemangiopericytomas 216  
 haematoxylin 449  
 haemoglobin A<sub>1c</sub> 185  
*Haemophilus influenzae* 97, 100  
 hamsters 13  
 Hashimoto's thyroiditis 387–8  
 HAT selection 19–20, 124–5  
 heart transplantation  
 immunohistology 276, 277, 280–4, 287  
 mab therapies 341–2, 343  
 heavy chains, immunoglobulin 2–3  
 gene rearrangements 5, 6  
 hepatitis  
 chronic autoimmune 416–17  
 diagnosis 249–50  
 hepatitis A virus (HAV) 249  
 hepatitis B surface antigen (HBsAg) 100, 128,  
 149, 249–50  
 hepatitis B virus (HBV)  
 diagnosis 249–50

- Humab 99, 100
  - therapy 267
- hepatitis C virus (HCV) 250
- hepatitis D virus (HDV) 250
- hepatitis E virus 250
- herpes simplex virus (HSV)
  - diagnostic assays 251, 252, 253, 254
  - therapy 267
- herpes (varicella) zoster virus (VSV) 96, 254, 267
- heteroconjugates, production 125–6
- heterohybridoma fusion partners 87, 88, 103
- heterophilic antibodies 191, 192
- high-dose hook phenomenon 193
- high pressure liquid chromatography (HPLC) 381–2
- histiocytoma, malignant fibrous (MFH) 217–18
- histogenesis, tumour 216–18
- HLA antigens
  - Humab 95–6
  - see also* major histocompatibility complex antigens
- HMB-45 mab 366–7
- HMFG1 mab 226, 228–9, 234
- HMFG2 mab 234, 235
- HMSA-1/HMSA-2 mab 367
- Hodgkin's disease 212
- hormone receptors
  - autoantibodies 389
  - epitope mapping 389–90
  - functional analysis 391
  - purification and characterization 389
- hormones
  - affinity purification 393
  - assays 380–2, 383–5
  - epitope mapping 389–90
  - functional analysis 391
  - modification of activity 393–5
  - enhancement 395
  - immunoneutralization 393–4
- Humab, *see* human monoclonal antibodies
- human anti-mouse antibodies (HAMA) 90, 155, 233–4, 418
- human antigens 13
- human B lymphocytes
  - activation 85
  - combined EBV/fusion technique 89, 103–4
  - EBV transformation 87–8, 103, 167
  - enrichment 98
  - fusion 85–7, 88, 101
  - immortalization methods 85–9, 101–4
  - in-vitro* immunization 99–101
  - in-vivo* immunization 99
  - source 98
- human gamma globulin (HGG) 406
- human–heterohybridoma fusion 87, 88, 103
- human–human fusion 85–6, 101–2, 167
- human immunodeficiency virus (HIV) 149
  - diagnostic tests 195, 254–5
  - gag* proteins 146
- human monoclonal antibodies (Humab)
  - 85–106, 127
  - advantages 90
  - to autoantigens 92–3
  - genetically engineered 101, 127
  - infectious diseases and 96–7
  - production 85–90, 167–8
    - bulk 105–6
    - problems 97–106
  - screening assays 97–8
  - transplantation and 95–6
  - to tumour antigens 93–5
  - use 90–7
- human–mouse fusion 87, 102, 167
- humanized monoclonal antibodies 7, 89–90, 127, 157, 166–70
  - chimeric 167, 168
  - complement-dependent region (CDR)
    - grafting 167, 168–70
  - immunogenicity 418–19
  - transplant recipients 351–2
  - tumour therapy 169, 230
- hybrid antibodies
  - applications 201–2
  - engineered 157–8
  - somatic cell production 15–16, 123–5
- hybridoma cells 7
  - bulk culture 25
  - cryopreservation 24–5, 431–2
  - generation, *see* fusion, cell
  - growth and selection 18–22
  - preservation 24–5
  - thawing 25
  - see also* cloning techniques; screening assays
- hybridoma growth factors 18
- hydrophilic groups 50
- hydrophilicity plots 61–2
- hypervariable regions, *see* complementarity determining regions
- hypoxanthine 19
- hypoxanthinephosphoribosyltransferase (HPRT) 19
- ichthyosis vulgaris 364–5
- idiotypic antibodies
  - endocrinological uses 391–2
  - immunoassays 189
  - tumour therapy 230–1
- IgG mab
  - affinity of multivalent 44–5, 47
  - fractionation into subclasses 453
- IgM capture immunoassays 252
- IgM mab
  - affinity of multivalent 46–7
  - human 102
  - phage display libraries and 149–51
  - purification 28
- imaging, tumour, *see* tumour imaging
- immortalization of human B lymphocytes 85–9, 101–4
- immune response 1–2, 403–6
  - control by mab 406–8
  - modulation, infectious diseases 268
  - primary 10
    - phage display 149–51
  - recapitulation *in vitro* 153–4
  - secondary 2, 10

- immunization 9–15
  - choice of host animals 13–14
  - frequency and timing 15
  - in vitro*, *see in-vitro* immunization
  - in vivo*, humans 99
  - routes 14–15
  - synthetic peptides 66
  - technique 429, 430
  - see also* adjuvants; antigen(s)
- immunoassays 180–202
  - ambient analyte 199
  - anti-immune complex 189, 190
  - antibody detection methods 197–201
    - enzyme labels 197–8
    - non-enzyme labels 199–200
  - bispecific mab 132, 201
  - competitive 189–90
  - convenience 196–7
  - endogenous interference 190–2
  - evanescent wave 200
  - fibre optic sensors 201
  - fluorescence-amplified enzyme-linked (FAELIA) 198, 199
  - future prospects 201–2
  - high-dose hook phenomenon 193
  - hormone 381–2, 383–5
  - IgM capture 252
  - labelling methods 194
  - non-labelling methods 200–1
  - pros and cons of using mab 183–5
  - sensitivity 194–5
  - small molecular weight analytes 188–90
  - specificity 185–8
  - speed 195–6
- immunocompromised patients, infections 253–5
- immunoconjugates 121–2
  - genetically engineered 157–8
  - tumour therapy 231–8
  - see also* immunotoxins
- immunodominant molecules 11
- immunofluorescence staining
  - mab screening 22, 448–9
  - sensitivity 41–2
- immunogens, *see* antigen(s)
- immunoglobulin superfamily of adhesion molecules 373
- immunoglobulins, *see* antibodies
- immunogold labelling 42
- immunohistochemistry
  - bispecific mab 132
  - endocrinology 385–6
  - graft-versus-host disease 328–9
  - mab screening 22, 67, 443–9
    - alkaline phosphatase staining 446–8
    - antigen fixation 444, 445
    - immunofluorescence staining 448–9
    - immunoperoxidase staining 445–6
    - recipes 449
    - storage of tissues/cells 445
    - tissue preparation 443–4
  - organ transplantation 274–87
  - quantified 218
  - sensitivity 41–2
  - skin/skin diseases 362–73
  - tumours 209–19
- immunomagnetic beads 324
- immunometric assays
  - hormones 382, 383, 384–5
  - selective antibody 190, 191
  - two-site 181, 188–9, 384–5
- immunoperoxidase staining 445–6
- immunoprecipitation, target antigens 31–2
- immunoradiometric assay (IRMA) 181–2
- immunotherapy 175, 406–8
  - experimental studies 292–309
  - graft-versus-host disease 319, 326–8
  - infectious diseases 260–9
  - organ transplant recipients 340–53
  - rheumatological disorders 403–21
  - tumours, *see* tumour therapy
- immunotoxins
  - graft-versus-host disease prophylaxis 323–4
  - graft-versus-host disease therapy 328
  - rheumatoid arthritis 412, 413–14
  - sFv fusion proteins 157–8
  - tumour therapy 236, 237
- in-vitro* immunization 14–15, 202
  - Humab production 99–101
  - synthetic peptides 65
- incubation times 56
- indium-111 (<sup>111</sup>In) 224, 225
- indium benzyl-EDTA (IBE) 130
- infections
  - immunocompromised patients 253–5
  - T cell-depleted patients 417–18
- infectious diseases 96–7
  - diagnosis 247–56
  - prophylaxis and therapy 260–9
- inflammatory bowel disease 416
- influenza viruses 248
- inhibin-A 382
- insulin
  - antibodies 393
  - assays 384, 385
  - Humab 92
  - receptors 391, 392
- insulin-like growth factor (IGF)-1 391, 394
- receptors 389, 391
- integrins 372
- intercellular adhesion molecule (ICAM-1; CD54) 404
  - mab 307, 308, 344–5, 413, 415
  - skin cells 373
  - transplanted organs 285–7
- interferon (IFN) 134
- interferon-gamma (IFN- $\gamma$ ) mab 266, 305, 306, 414
- interleukin-1 (IL-1) 287, 385
- interleukin-2 287
  - fusion proteins 157, 352
- interleukin 2 receptors (IL-2R)
  - $\alpha$  chain (Tac; p55) 347–8, 350, 351, 352–3
  - $\beta$  chain 348
  - mab 275, 394
    - animal model of arthritis 301, 409
    - animal models of autoimmunity 301, 303
    - graft-versus-host disease prophylaxis 325–6
    - graft-versus-host disease therapy 327–8



- rheumatoid arthritis 412  
   transplant recipients 347–51, 352–3  
 interleukin-3 (IL-3) 394  
 interleukin-4 (IL-4) mab 305–8, 394  
 interleukin-5 (IL-5)  
   mab 394  
   receptors 394  
 interleukin-6 (IL-6) mab 266, 394  
   rheumatoid arthritis 413, 414  
 interleukin-6 (IL-6) receptor mab 394  
 interleukins 385  
 intravenous immunoglobulin (IVIG) 266  
 iodine-123 (<sup>123</sup>I) 224–5  
 iodine-125 (<sup>125</sup>I)  
   antibody labelling 224–5, 232  
   antigen labelling 31  
 iodine-131 (<sup>131</sup>I) 232, 233, 234  
 iodonitrophenylacetyl (NIP) 128, 135–6  
 ion exchange chromatography 28  
 ionic strength, affinity and 48–9  
 isoenzymes, differentiation between 187  
 isotype determination 26, 449–50  
  
 Janusins 158  
 Jerne's idiotypic hypothesis 230  
 Jessner's lymphocytic infiltrate 371–2  
  
*k* (rate constant) 37–8  
*K<sub>a</sub>* 34–6  
*K<sub>d</sub>* 36–7  
 keratinocytes 362–6  
   adhesion molecules 373  
 keratins 363–5  
 keyhole limpet haemocyanin (KLH) 63, 78–81  
 KF1 mab 369–70  
 Ki67 mab 216  
 kidney transplantation  
   immunohistology 274–5, 278–9, 287  
   mab therapies 341, 342, 343, 345–6, 348–50  
   kinetics, antigen–antibody interactions 37–40  
   *Klebsiella* infections 261  
   KR12 heterohybridoma cells 103  
   Ks8.12 mab 364, 365  
  
 L1 antigen 365  
 L243 mab 278, 281  
 Laemmli method 30  
 Lag mab 368  
 Langerhans cells (LC) 367–8  
*Legionella pneumophila* 248  
 leishmaniasis 268  
 leprosy (*Mycobacterium leprae*) 97, 99  
 Letterer–Siwe disease 368  
 Leu 2 mab 299, 323  
 Leu 4 mab 275, 277  
 Leu 8 mab 275, 371  
 Leu 9 mab 371  
 leucine zippers 159, 160  
 leukaemia 230, 317  
 LFA-1, *see* lymphocyte function-associated  
   antigen 1  
 LH1/LH2/LH6/LH8 mab 364  
 LH7:2 mab 370  
  
 light chains, immunoglobulin 2–3  
   gene rearrangements 5  
   restriction, B cell lymphoproliferations 213  
 limiting dilution 23, 104–5, 436–8  
   by set concentration 437–8  
   by titration 436–7  
 lipid A, endotoxin 96, 261–2, 264  
 lipids 11  
 lipopolysaccharide, *see* endotoxin  
*Listeria monocytogenes* 251  
 liver transplantation  
   immunohistology 276, 285, 287  
   mab therapies 346, 350–1  
   LL001/LL002 mab 364  
   LN-3 mab 329  
   LP 34 mab 365  
 lung carcinoma 228–9  
 lung transplantation 284–5  
 lupus erythematosus 371–2  
   systemic, *see* systemic lupus erythematosus  
 luteinizing hormone (LH) 188, 196–7, 391  
   receptors 389  
 Ly5 mab 308, 309  
 lymph nodes 14, 202  
 lymphoblastoid cell lines (LCL) 86, 89, 101–2,  
   103  
   cloning 105  
   EBV-transformed 86, 88, 167–8  
 lymphocyte function-associated antigen 1  
   (LFA-1) 344, 404, 405–6  
   mab 307, 308, 326, 344–5, 353, 406  
 lymphocyte function-associated antigen 3  
   (LFA-3) 373, 404  
 lymphokines 404–5  
   *see also* cytokines  
 lymphoma  
   cutaneous T cell (CTCL) 227, 371  
   diagnosis 213, 214  
   prognostic markers 216, 218  
   therapy 133, 169, 230–1, 236  
 lymphoproliferative disorders  
   light chain restriction 213  
   transplant recipients 326–7, 343, 418  
 lysine 65  
 lysozyme 169, 174  
   epitopes 51  
   sFv antibody 147, 152–3  
 Lyt-1.2 mab 321  
  
 M-T412 mab 411, 412, 417, 418  
 mab, *see* monoclonal antibodies  
 MAC 387 mab 365–6  
 macrophages  
   infiltrating transplanted organs 274, 275, 276  
   mab, animal models of autoimmunity 304,  
   305  
   peritoneal 18, 437, 438  
   isolation 435  
 magnetic monosized polymer microspheres 324  
 major histocompatibility complex (MHC)  
   antigens 96, 403–4  
   transplanted organs 276–85  
 major histocompatibility complex (MHC) class  
   I antigens 403–4

- MHC class I antigens (*cont.*)  
 expression  
 normal tissues 278–9, 280, 281, 285  
 transplanted organs 279, 280–4, 285  
 major histocompatibility complex (MHC) class II antigens 404  
 expression  
 graft-versus-host disease 329  
 normal tissues 278, 279, 280, 281, 285  
 skin cells 365, 367–8  
 transplanted organs 279, 280–2, 284–5  
 mab therapies  
 animal models of autoimmunity 302–3, 304, 406  
 animal models of rheumatological disorders 408, 409  
 peptides binding 145  
 malaria 97, 99, 268  
*m*-maleimidobenzoic acid  
*N*-hydroxysuccinimide ester (MBS) 64, 79–80  
 malignant fibrous histiocytoma (MFH) 217–18  
 mass production, *see* bulk production  
 MAX.16H5 mab 411, 415  
 measles 267  
 media, cell fusion 18, 429–30  
 Mel 14 mab 308, 309  
 melanocytes 366–7  
 melanoma  
 diagnosis 94, 366, 367  
 ICAM-1 expression 373  
 therapy 94, 230  
 memory B cells 2, 149  
 meningitis 250–1  
 metabolic labelling, target antigens 32  
 methionine, radiolabelled (<sup>35</sup>S-methionine) 32  
 methotrexate (MTX) 417  
 antibody-conjugated 236  
 graft-versus-host disease prophylaxis 319, 322, 323  
 MHC, *see* major histocompatibility complex  
 microspot assay, multianalyte 199–200  
 mimetic 175  
 minimal recognition unit (MRU) 170, 171, 174–5  
 mitogens 85, 100  
 mixed-isotype bispecific antibodies 134–5  
 mono-*t*-butyloxycarbonyl-1,6-diaminohexane (HMD) 71  
 monoclonal antibodies (mab) 6–7  
 analysis of structure of target antigen 31–2  
 characterization 26–30, 449–58  
 production, *see* production of mab  
 purification, *see* purification, mab  
 storage 30–1  
 monocytes 274, 275, 409  
 mononuclear cells 104  
 mouse antigens 13  
 mouse monoclonal antibodies (Mumab) 13  
 disadvantages 90  
 human antibody responses 90, 155, 233–4, 418  
 humanized 89–90, 127, 168  
*see also* humanized monoclonal antibodies  
 tumour therapy 230  
 multianalyte microspot assay 199–200  
 Multipin system 70, 71–6  
 multivalency, mab affinity 44–8  
 muramyl dipeptide 100  
 MY7 mab 371  
 myasthenia gravis 93  
 experimental autoimmune (EAMG) 294, 297, 406  
*myc* oncoproteins 67–9, 74, 77  
*Mycobacterium leprae* (leprosy) 97, 99  
 mycological infections 255  
 mycoplasma, tissue culture contamination 431  
*Mycoplasma pneumoniae* 248  
 myelin basic protein (MBP) 302, 304  
 myeloma 394  
 myeloma cells  
 choice 13, 15–16  
 human 85–6, 102, 103  
 mouse 87, 102, 103  
 removal of unfused 19–20  
 thawing 16, 433  
*see also* fusion, cell  
 myelosuppression, selective radiotherapy 233–4  
 myosin heavy chain fragments 187  
 myxoedema, primary 392  
  
*Naegleria fowleri* 268  
 naevae, melanocytic 366, 367  
 natural killer (NK) cells, transplanted organs 274, 275  
*Neisseria gonorrhoeae* 253  
 nephritis, autoimmune 297, 301, 304, 305, 307, 308  
 neuritis, experimental autoimmune (EAN) 293, 294, 295, 297, 299  
 neuroendocrine cells 388  
 neurological infections 250–2  
 neuropeptides 386, 388  
 neurotransmitters, mab to 52  
 NEWM myeloma protein 169  
 nitrocellulose membranes  
 adjuvant activity 12  
 protein transfer to 463–4  
 NK1 C3 mab 366  
 non-specific enolase 366  
 NP-cap (4-hydroxy-3-nitrophen-acetyl caproic acid) 169  
 nude mice 223  
  
 oestradiol 185, 189, 190  
 oestriol 185  
 off rates 37–8  
 OKM1 mab 275, 276  
 OKT3 F(ab')<sub>2</sub> fragments 343–4  
 OKT3 mab 275, 325, 326–7, 340  
 adverse effects 342–3, 418  
 recipient antibodies 343  
 transplant recipients 341–3, 352  
 OKT4 mab 275, 296  
 OKT6 mab 368  
 OKT8 mab 275  
 OKT10 mab 371  
 OKT 11<sub>a</sub>-R mab 324

- oligonucleotide primers 127–8, 146–7, 172–3  
 on rates 37–8  
 oncoproteins 67–9  
 Optivant 12  
 ovalbumin 63  
 ovarian carcinoma 234–5  
 ‘over-the-counter’ pregnancy tests 196, 197  
 OX7 Fab 49  
 OX7 F(ab')<sub>2</sub> 49  
 Ox42 mab 304, 305
- p53 protein 145, 213–14, 215  
 PAL-M1/PAL-M2 mab 367  
 pan T cell mab  
 animal models of autoimmune diseases 293, 294  
 rheumatoid arthritis 412–14  
 transplant recipients 341–6  
 pancreas transplantation 346, 350  
 pancreatic cancer 217  
 paraformaldehyde 53  
 parainfluenza viruses 248  
 parasitic infections 268  
 parathyroid hormone (PTH) 188, 383, 384  
 parathyroid hormone-related protein 382  
 pepscan 70  
 pepsin 453–4  
 peptide-derived antibodies, synthetic 52, 60–82  
 epitope detection and analysis 69–77  
 production 60–9, 78–82  
 screening 66–9  
 peptides  
 identification of new 388–9  
 phage display 144–5  
 phage display libraries 145–6  
 synthetic 52, 382  
 conjugation to carrier molecules 63–5, 78–82  
 generation of immunogenic 65  
 immunization schedules 66  
 selection 61–3  
 periodate-lysine-paraformaldehyde fixative 53  
 periplasm, bacterial 144  
 peroxidase 21, 445–6  
 pH, affinity and 48–9  
 phage  
 antibody fragment display 147–8  
 antibody selection on 146–54  
 as expression vectors 144–6  
 filamentous 143–4  
 life cycle 144  
 peptide display 144–5  
 protein display 146  
 structure 143  
 phage display libraries 7, 142–59, 176  
 affinity maturation of antibodies 150, 151–2  
 nature of antibody fragments produced 155  
 peptide 145–6  
 selection of novel antibodies from 148–9  
 tapping primary immune response 149–51  
 phenotype 209–10  
 ortho-phenyl diamine (OPD) 21, 442, 443  
 o-phenylenedimaleimide 126  
 phenylloxazalone 148–9  
 phenytoin 201  
 phosphorus-32 (<sup>32</sup>P) 232  
 pituitary adenomas 386  
 plasma cells 2  
 plasmid vectors 168, 173  
 plasminogen activator, tissue (tPA) 133–4  
*Plasmodium falciparum* 97  
 platelet endothelial cell adhesion molecule (PECAM; CD31) 280, 282, 285–7  
 pneumococcus 97, 99  
*Pneumocystis carinii* pneumonia 255  
 pokeweed mitogen (PWM) 85, 100  
 polyacrylamide gel electrophoresis with sodium dodecyl sulphate (SDS–PAGE) 21, 29–30, 459–64  
 minigel method 459–62  
 recipes 462–3  
 Western blotting 463–6  
 polychondritis, relapsing 417  
 polyclonal antibodies 6–7  
 immunoassays 182, 183–5, 383  
 tumour targeting 222, 224  
 polyethylene glycol (PEG) 17, 85, 101, 433, 434–5  
 polymerase chain reaction (PCR) 176  
 antibody V region cloning 146–7, 172–3  
 bispecific mab production 127–8, 129  
 error-prone 152  
 precipitation, fixation by 53  
 pregnancy tests, ‘over-the-counter’ 196, 197  
 pristane 25, 441  
 pro-opiomelanocortin 385  
 prodrugs, tumour therapy 237–8  
 production of mab 7, 9–32  
 bispecific 123–31  
 bulk 25–6, 105–6, 440–1  
 endocrinology 382–3  
 human 85–90, 97–106, 167–8  
 methods 429–66  
 phage display libraries 142–59  
 to synthetic peptides 60–9, 78–82  
 progesterone 392, 394  
 prognostic markers, tumours 214–16  
 proinsulin 198, 385  
 prolactin 193, 384, 390, 392, 394  
 proliferating cell nuclear antigen (PCNA) 211–12, 216  
 proline 62  
 prostate-specific antigen (PSA) 186  
 prostatic acid phosphatase 100  
 protein A affinity chromatography 28–9, 451–2, 453  
 protein G affinity chromatography 28–9, 452–3  
 proteins 11  
 antigenic determinants, *see* epitopes  
 determination of concentration 29  
 fusion 157–8  
 phage display 146  
 recognition by anti-peptide antibodies 52  
*Proteus* infections 261  
 protozoa 97  
*Pseudomonas aeruginosa* 97, 261, 266  
 psoriasis 416  
 pta-3 mab 301, 303

- purification  
   bispecific mab 125  
   hormone receptors 389  
   hormones 393  
   mab 26–9, 449–58  
     chromatographic methods 27–9, 451–3, 455–7  
     salt fractionation 27, 450–1  
   purified protein derivative of tuberculin 63–4, 97
- quality control, immunohistochemistry 211, 213  
 Quilty effect 276
- R6.5 mab 345  
 rabies 251  
 radioimmunoassays 180–1, 182, 382  
   bispecific mab 132  
 radioisotopes 180–1  
   tumour localization 224–6  
   tumour therapy 231–5  
 radiolabelled mab  
   tumour imaging 223, 224–7  
   tumour therapy 231–5  
 RaK1/RaK5 mab 364  
 rat antigens 13  
 rat monoclonal antibodies 13  
 rate constant ( $k$ ) 37–8  
 receptors  
   blocking antibody fragments 155  
   hormone, *see* hormone receptors  
 recombinant DNA technology 142  
   *see also* genetic engineering; phage display libraries  
 rejection, graft, *see* graft rejection  
 reovirus type 3 receptor 175  
 ‘reprogramming’, immune system 407  
 respiratory infections, diagnosis 247–8  
 respiratory syncytial virus (RSV) 247–8  
 retrovirus type 3 175  
 RFD7 mab 276  
 RFT2 mab 345  
 rhenium-188 ( $^{188}\text{Re}$ ) 232, 234  
 Rhesus D antibodies 90–2, 99, 169–70  
 rheumatoid arthritis (RA)  
   animal models 409–10  
     anti-CD4 mab 294, 297, 406, 409–10  
     anti-IL2R mab 301, 303  
     anti-T cell receptor mab 298–9  
     cytokine-directed mab 305, 306  
   clinical studies 410–17, 418  
 rheumatoid factor 93, 192  
 rheumatological disorders 403–21  
   adverse effects of mab 417–19  
   animal studies 408–10  
   clinical studies 410–17  
   future prospects 419  
   potential therapeutic targets 405  
 ricin 323–4  
   A chain 236, 324, 328, 413–14  
 rotaviruses 248–9  
 routes of administration  
   antigens for immunization 14–15  
   radiolabelled mab 227, 232–3  
   rubella 252, 267
- S200 column  
   care 457  
   preparation and use 455–6  
 S-100 protein 366, 368  
 S-antigen 305, 306  
*Salmonella* gastroenteritis 249  
*Salmonella minnesota* R595 strain 262, 263  
 salt fractionation 27, 450–1  
 saporin 133  
 schistosomiasis 268  
 screening assays 20–2  
   Humab 97–8  
   mab against cellular/insoluble antigens 22  
   mab against soluble antigens 21–2  
   peptide-derived antibodies 66–9  
   techniques 441–9  
 SDS-PAGE, *see* polyacrylamide gel electrophoresis with sodium dodecyl sulphate  
 secondary antibodies 383–4, 449  
   kinetics of reactions 40  
   quality 42  
   selection methods 19–20  
     bispecific mab 124–5, 128, 130  
 selective antibody immunometric assay 190, 191  
 Sendai virus 17, 267  
 sensitivity 41–4  
   affinity and 44  
   different detection systems 41–2  
   immunoassays using mab 194–5, 199–200  
 sepharose 4B, CNBr-activated, mab coupling to 457–8  
 septic shock 261–6  
 791T/36 mab 236  
 sexually transmitted diseases 252–3  
 single cell manipulation, cloning by 23, 439–40  
 single chain antibodies 7  
   bispecific 131  
 single chain Fv fragments (sFv) 156, 170, 171  
   applications 155  
   bacterial display 152–3  
   bivalent 159, 160  
   engineering of effector functions 157–8  
   expression 173–4  
   phage display 147  
   phage display libraries 149, 155  
   production 154  
 single domain antibodies (dAb) 170, 171  
   expression 173–4  
 size exclusion chromatography 27–8, 455–7  
 Sjögren’s syndrome 416  
 skin 362–73  
   adhesion molecules 372–3  
   basement membrane zone (BMZ) 368–70  
   infiltrates 370–2  
   structure 362, 363  
 SLE, *see* systemic lupus erythematosus  
 small molecules  
   antibodies to 52  
   immunoassay methods 188–90, 191  
 smears 444, 445

- sodium borate-buffered saline 82  
sodium hydrogen carbonate buffer 81  
sodium phosphate buffers 81–2  
sodium sulphate 27  
soft agar, cloning in 438–9  
solid phase antigens 44–7, 56  
somatic cell hybridization 123–5  
somatostatin 202, 386  
specificity  
  antibody–antigen interactions 53–6  
  hormone assays 381–2  
  immunoassays 185–8  
spectrophotometry 29  
spleen 14  
  direct injection of antigens 202  
  spleen cell:myeloma cell ratio 17  
  spleen cells 14  
  isolation method 433–4  
  phage antibodies derived from 148–9, 176  
  removal of unfused 19–20  
SPOTs system 70–1, 76–7, 78  
steroids  
  graft-versus-host disease therapy 319  
  OKT3 side-effects 343  
  transplant recipients 349, 350  
storage, mab 30–1  
streptavidin 43, 145, 228–9  
streptococci  
  group A 97  
  group B 250–1, 266  
streptozotocin (STZ)-induced diabetes 295,  
  296, 298, 302  
N-succinyl 3-(2-pyridyldithio) propionate  
  (SPDP) 126  
surface plasmon oscillation 200–1  
synthetic peptides, *see* peptides, synthetic  
syphilis 253  
systemic lupus erythematosus (SLE)  
  animal models 308, 309, 408–9  
  anti-CD4 mab 294, 296, 408  
  anti-CD8 mab 295, 299  
  anti-cytokine therapies 305–8  
  anti-IL-2R mab 301  
  antigen-presenting cell-directed mab 303,  
  304, 406, 408  
  pan T cell mab 293, 294, 408  
  clinical studies 415  
  
T11 mab 322  
T12 mab 320, 341  
T101 immunotoxin 324  
T cell mab 406  
  adverse effects 417–19  
  animal models of autoimmunity 294–303,  
  406, 407  
  animal models of rheumatological disorders  
  408–10  
  graft-versus-host disease prophylaxis 319–26  
  graft-versus-host disease therapy 326–7  
  prophylaxis/therapy of graft rejection 340–53  
  tolerance induction 406–8  
  *see also* pan T cell mab; *specific mab*  
T cell receptor (TCR) 404  
  
 $\beta$  chain restriction 213  
mab  
  animal model of arthritis 298–9, 409–10,  
  412  
  animal models of autoimmunity 298–9,  
  300–2  
  transplant recipients 343  
T cells  
  activation 10, 403–5  
  activation markers 301, 302, 412  
  congenital deficiency disorders 323  
  depletion  
  adverse effects 417–18  
  donor bone marrow *ex vivo* 319–25  
  *in-vitro* immunization and 100  
  EBV-specific cytotoxic 103  
  infiltrating transplanted organs 274–6, 277  
  *see also* CD4 T cells; CD8 T cells  
Tac (IL-2R  $\alpha$  chain; p55) 347–8, 350, 351,  
  352–3  
targeting of tumours, *see* tumour targeting  
technetium-99m ( $^{99m}\text{Tc}$ ) 224, 225–6  
temperature, antibody–antigen interactions and  
  48, 56  
10.18 anti-clonotypic antibody 299, 302  
tetanus toxoid 96, 99, 100, 149  
thawing cells 16, 25, 432  
theophylline 201  
33B3.1 mab 348–50, 353  
33B3.11 mab 325–6  
35.1-R immunotoxin 324  
36-7 Fab' 49  
36-7 F(ab')<sub>2</sub> 49  
3T3 fibroblasts 18  
Thy-1 mab 49, 294, 321  
  animal models of rheumatological disorders  
  408, 409  
  bispecific 134  
Thy 1.2 mab 293, 321  
thymidine 19  
thymocytes, rat 18  
thyroid disease  
  autoimmune (AITD) 387–8, 392  
  diagnosis 384  
  Humab generation 92–3  
  thyroid peroxidase (TPO) 387  
  thyroid-stimulating hormone (TSH)  
  anti-idiotypic antibodies 392  
  enhancement of activity 395  
  immunoassays 182, 183, 195, 198, 199, 384  
  thyroid-stimulating hormone (TSH) receptor  
  autoantibodies 389, 392  
  mab 92–3, 392  
  thyroiditis, experimental autoimmune (EAT),  
  *see* experimental autoimmune  
  thyroiditis  
thyroxine 189  
time resolution fluorimetry 199  
tissue culture  
  bulk 25, 440–1  
  contamination 430–1  
  Humab production 105–6  
  sterile technique 429–30  
tissue plasminogen activator (tPA) 133–4

- tissue sections  
 heating 211–12  
 preparation 443–4  
 storage 445
- tolerance induction 406–8
- tolidine, bis-diazotized (Bdt) 64–5, 80–1
- toxins  
 antibody-conjugated, *see* immunotoxins  
 bispecific mab-specific 352
- toxoplasmosis (*Toxoplasma gondii*) 252, 255, 268
- transfectoma cells 168  
 bispecific mab-secreting 128, 129, 130
- transformation, Epstein–Barr virus (EBV) 87–8, 103
- transforming growth factor 382–3
- transforming growth factor-beta (TGF- $\beta$ ) mab 414
- transplantation  
 clinical studies of mab therapies 340–53, 418  
 graft-versus-host disease 317–29  
 Humab and 95–6  
 immunohistology 274–87  
 adhesion molecules 285–7  
 cellular infiltrates 274–6  
 cytokines 287  
 MHC antigens 276–85  
 infections following 253–5  
*Treponema pallidum* 253  
 trinitrophenol (TNP) 168  
 Tris-buffered saline (TBS) 449  
 TSH, *see* thyroid-stimulating hormone
- tumour antigens  
 classes 94  
 cytoplasmic/surface membrane 95  
 Humab 93–5  
 immunoassays 186
- tumour imaging (immunoscintigraphy) 223–9  
 animal studies 223  
 antibody fragments 155, 223, 226–7  
 bispecific antibodies 122, 228  
 choice of radioisotopes 224–6  
 clinical studies 224–9  
 routes of mab administration 227  
 two-step strategies 227–9
- tumour necrosis factor (TNF) 264, 287  
 mab 265–6, 305, 306, 343
- tumour necrosis factor-alpha (TNF- $\alpha$ ) mab 327, 328  
 experimental allergic uveitis 305, 306  
 rheumatoid arthritis 413, 414
- tumour necrosis factor-beta (TNF- $\beta$ ) 381, 394
- tumour pathology 209–19  
 benign versus malignant 213–14  
 diagnostic 210–14  
 educational 214  
 future prospects 218  
 histogenesis versus differentiation 216–18  
 prognostic markers 214–16
- tumour targeting 222–38  
 bispecific mab 122, 132–4  
 immunoconjugates 121  
*see also* tumour imaging; tumour therapy
- tumour therapy 93–4, 229–38  
 bispecific mab 122, 132, 133, 230, 236  
 conjugated antibodies 231–8  
 amplification systems 237–8  
 antibody–drug 235–6  
 antibody–toxin 236, 237  
 radioisotopes 231–5  
 humanized mab 169, 230  
 unconjugated mab 229–31
- 25-3 mab 344–5  
 27-11 Fab' 49  
 27-11 F(ab')<sub>2</sub> 49
- two-site immunometric assay 181, 188–9, 384–5
- tyrosine 62
- U-266 myeloma cells 85–6
- ultramicroanalysis 194–5
- ultrasensitivity, immunoassays 199–200
- universal bispecific antibodies 135–6
- uveitis, experimental allergic (EAU), *see* experimental allergic uveitis
- V domains, *see* variable (V) regions
- variable (V) region genes  
 bispecific mab generation 127–30  
 cloning 127–8, 146–7, 172–3  
 rearrangements 5, 6
- variable (V) regions 3  
 chain shuffling 151–2
- varicella (herpes) zoster virus (VSV) 96, 254, 267
- vascular cell adhesion molecule 1 (VCAM-1) 285, 287, 405–6
- vasculitis, systemic 415–16, 419
- vinca alkaloids 133
- viral infections  
 diagnosis 248–50, 251–2, 254–5  
 prophylaxis and therapy 266–8  
 transplant recipients 276, 349, 353
- viruses  
 effector cell targeting 132  
 Humab 96
- VLA molecules 372, 405–6
- VLA-4 mab 307, 308
- von Willebrand's factor (vWF) 280
- W3/13 mab 49, 293  
 W3/25 mab 49, 296, 297  
 W6/32 mab 278, 281, 283
- Western blotting 461, 462, 463–6  
 analysis of target antigens 31  
 immunostaining 465  
 protein transfer from SDS–PAGE 463–4  
 recipes 466  
 screening assay 21–2, 67
- XomaZyme-H65 323, 328
- yeast, tissue culture contamination 431
- yields  
 bispecific mab 124, 126, 130–1  
 recombinant antibody fragments 154–5  
 yttrium-90 (<sup>90</sup>Y) 232, 233, 234